Concerns about the Amyloid Cascade Hypothesis and Reappraisals-Reference-Cited by-同舟云学术

Concerns about the Amyloid Cascade Hypothesis and Reappraisals

Published:2023 Issue: Volume: Page:167-183
ISSN:
Container-title:Alzheimer’s Disease Research
language:
Short-container-title:

Author:

Behl Christian

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/978-3-031-31570-1_10

Reference40 articles.

1. Alzforum (2012, October 30) Therapeutics: Flurizan™. https://www.alzforum.org/therapeutics/flurizan. Accessed 21 January 2023

2. Behl C (2017) Amyloid in Alzheimer's disease: guilty beyond reasonable doubt? Trends Pharmacol Sci 38:849–851. https://doi.org/10.1016/j.tips.2017.07.002

3. Cataldo AM, Barnett JL, Pieroni C, Nixon RA (1997) Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer’s disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J Neurosci 17:6142–6151. https://doi.org/10.1523/JNEUROSCI.17-16-06142.1997

4. Distillations (2019) The Alzheimer’s Copernicus problem: thirty years of research have failed to solve the Alzheimer’s riddle. Is the problem a blind embrace of scientific dogma? [podcast transcript of Distillations episode 244]. Science History Institute. https://www.sciencehistory.org/distillations/podcast/the-alzheimers-copernicus-problem. Accessed 21 Jan 2023

5. Fillit H, Green A (2021) Aducanumab and the FDA–where are we now? Nat Rev Neurol 17:129–130. https://doi.org/10.1038/s41582-020-00454-9

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The cost and benefit of targeting amyloid plaques to treat alzheimer’s disease;Annals of Alzheimer's and Dementia Care;2023-12-30